Deaths have been reported in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment and are treated with somatropin. 患严重肥胖或严重呼吸损伤的帕-魏二氏综合症,并使用生长激素治疗患者中,有死亡病例的报导。
Somatropin should not be used for growth promotion in pediatric patients with closed epiphysis or in patients with active proliferative or severe non-proliferative diabetic retinopathy. 生长激素不应用于儿科闭合骺患者,活性增生或严重非增生糖尿病视网膜病患者的生长促进。
The review will look into all available data on somatropin to reassess the benefit-risk balance of these medicines. 这个在审查将会调查所有关于生长激素的可获得数据来重新评价这些药物的利弊权重。
The study results suggest an increased risk of mortality with somatropin therapy compared to the general population. 这个研究提出与普通人群相比使用生长激素治疗有增加死亡率的风险。
Blood glucose levels should be monitored periodically as treatment with somatropin may decrease insulin sensitivity. 生长激素能降低胰岛素的敏感性,因此应周期性监测血糖水平。
Doses of insulin or oral agents may need to be adjusted for patients with diabetes on somatropin therapy. 患有糖尿病并进行生长激素治疗的患者,需要调节胰岛素或口服剂的剂量。
Somatropin is used to treat a number of conditions associated with a lack of growth hormone and short stature. 促生长激素被用来治疗一系列与生长激素缺乏和身材短小相关的症状。
Funduscopic examination should be performed routinely before initiating and periodically during the course of somatropin therapy. 在启动前应进行常规的眼底镜检查,并在生长激素治疗期间周期性检查。
Elderly patients may be more sensitive to the actions of somatropin and may be more prone to develop adverse reactions. 老年患者对生长激素的作用会更敏感,而且会更易于出现不良反应。
Any child having onset of a limp or complaints of hip or knee pain during somatropin therapy should be carefully evaluated. 在生长激素治疗期间,出现跛行或诉说髋关节、膝关节疼痛的儿童,应谨慎评估。
Norditropin should not be used in patients with known hypersensitivity to somatropin or any of its excipients. Norditropin不应用于已知对生长激素或其中任何辅料过敏的患者。
In patients with GHD, central ( secondary) hypothyroidism may first become evident or worsen during somatropin treatment. 患有GHD的患者,在采用生长激素治疗时,中央(次级)肾上腺机能衰退会首次变得明显或恶化。
Somatropin has not been shown to increase the occurrence of scoliosis. 生长激素并未显示出提高脊柱侧凸的发生率。
Patients with preexisting diabetes or glucose intolerance should be monitored closely during somatropin therapy. 患糖尿病或葡萄糖耐受不良的患者,在生长激素治疗期间应严密监测。
Patients treated with somatropin should therefore have periodic thyroid function tests and thyroid hormone replacement therapy should be initiated or adjusted as needed. 因此采用生长激素治疗的患者应该进行周期性的甲状腺机能试验,如果需要,应启动或调节甲状腺激素替代治疗。
Clinical Observation with Recombinant Human Somatropin for Severe Burns 重组人生长激素用于特重烧伤病人的临床观察
Application of recombinant somatropin to mechanical ventilated patients 重组人生长激素在机械通气病人中的应用
Serum IGFBP 3 protease activity in GHD increased to ( 29.0 ± 6.8)% after treatment with recombining human somatropin ( rhGH) for six months. 用重组人GH(rhGH)治疗6个月后,GHD患者的血清IGFBP3蛋白酶活性上升至(29.0±6.8)%。